Table 3.
Characteristics of 49 patients with resection
| Factors | R (n = 26) | BR (n = 17) | LA (n = 6) | p value |
|---|---|---|---|---|
| Age (years) | 72 (44–87) | 70 (51–80) | 65 (53–84) | 0.478 |
| Gender (male / female) | 14 / 12 | 9 / 8 | 4 / 2 | 0.830 |
| Biliary drainage (%) | 24 (92.3%) | 11 (64.7%) | 5 (83.3%) | 0.073 |
| Adjuvant therapy (%) | 6 (23.1%) | 15 (88.2%) | 6 (100%) | < 0.001* |
| Chemotherapy | 6 | 15 | 4 | |
| Chemoradiotherapy | 0 | 0 | 2 | |
| Portal vein embolization (%) | 2 (7.7%) | 4 (23.5%) | 1 (14.3%) | 0.344 |
| Preoperative blood examination | ||||
| Neutrophil-to-lymphocyte ratio | 2.31 (0.97–8.15) | 2.43 (1.52–6.15) | 3.86 (0.99–6.46) | 0.276 |
| Prognostic nuritional index | 42.4 (33.9–55.6) | 43.8 (36.3–50.1) | 42.6 (32.7–46.8) | 0.707 |
| CEA (mg/dl) | 3.0 (0.5–30.8) | 3.7 (1.5–24.4) | 2.6 (2.2–5.4) | 0.644 |
| CA19–9 (U/ml) | 59.6 (12.6–11,659) | 69.7 (1–1158) | 196.6 (8.0–669.3) | 0.715 |
| Histological differentiation | 0.473 | |||
| G1/2 (%) | 24 (96.0%) | 15 (88.2%) | 6 (100%) | |
| G3 (%) | 1 (4.0%) | 2 (11.8%) | 0 | |
| Pathological finding | ||||
| pT4 (%) | 2 (7.7%) | 7 (41.2%) | 3 (50.0%) | 0.013* |
| Lymph node metastasis (%) | 9 (34.6%) | 11 (64.7%) | 3 (50.0%) | 0.152 |
| Intrahepatic metastasis (%) | 1 (3.8%) | 2 (11.8%) | 0 | 0.457 |
| Residual tumor | ||||
| R0 (%) | 16 (61.5%) | 12 (70.6%) | 4 (66.7%) | 0.828 |
| R1 | 6 | 3 | 1 | |
| R2 | 4 | 2 | 1 | |
R: resectable, BR: borderline resectable, LA: locally advanced * R vs. BR, UR
CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, R0 complete resection, R1: microscopic residual tumor resection, R2: macroscopic residual tumor resection or distant metastasis (intrahepatic metastasis)